Media and briefings
![](https://ptxtherapeutics.com/wp-content/uploads/2024/07/ii-300x174.jpeg)
Prescient Therapeutics appoints accomplished medical professional Dr Gavin Shepherd as a director
Prescient Therapeutics Ltd (ASX:PTX, OTC:PSTTF), a clinical-stage oncology company developing personalised therapies for cancer, has appointed accomplished medical professional Dr ...
Read More
Read More
![](https://ptxtherapeutics.com/wp-content/uploads/2024/07/ii.jpeg)
Prescient Therapeutics appoints accomplished medical professional Dr Gavin Shepherd as a director
Prescient Therapeutics Ltd (ASX:PTX, OTC:PSTTF), a clinical-stage oncology company developing personalised therapies for cancer, has appointed accomplished medical professional Dr ...
Read More
Read More
![](https://ptxtherapeutics.com/wp-content/uploads/2024/05/AdobeStock_293584799-1024x591.jpg)
Prescient Therapeutics: Current Developments in Cancer Treatment
Prescient Therapeutics, an ASX-listed company, is engaged in the development of drugs targeting various forms of cancer, with a specific ...
Read More
Read More
![](https://ptxtherapeutics.com/wp-content/uploads/2023/06/maxresdefault-1024x576.jpg)
Prescient Therapeutics PTX-100 shows promising results in Phase 1b study
Prescient Therapeutics Ltd (ASX:PTX, OTC:PSTTF) CEO and managing director Steven Yatomi-Clarke sits down with Jonathan Jackson in the Proactive studio ahead ...
Read More
Read More
![](https://ptxtherapeutics.com/wp-content/uploads/2024/05/imm.jpeg)
Prescient Therapeutics to present PTX-100 results at T-Cell Lymphoma Forum in California
Clinical-stage oncology company Prescient Therapeutics Ltd (ASX:PTX, OTC:PSTTF) has been invited to present PTX-100 Phase 1b results at the 15th Annual T-Cell ...
Read More
Read More
![](https://ptxtherapeutics.com/wp-content/uploads/2020/07/logo.png)
STAY UP TO DATE
Register your details to receive company updates from Prescient Therapeutics